RSS   Newsletter   Contact   Advertise with us
Post Online Media

Amicus Therapeutics appoints VP, regulatory strategy

Amicus TherapeuticsAmicus Therapeutics, Inc., a biotechnology company, has appointed Andrew E. Mulberg as vice president, regulatory strategy.
Article continues below

READ MORE Amicus Therapeutics appoints Margaret G. McGlynn to board of directors

Dr. Mulberg is a pediatric gastroenterologist who has spent the past 6 years working at the U.S. Food and Drug Administration (FDA), most recently as Deputy Director of the Division of Gastroenterology and Inborn Errors Products. Dr. Mulberg will serve as a member of the executive team.

In addition to Dr. Mulberg's FDA experience, he previously held various roles of increasing responsibility within global drug development and medical affairs at leading pharmaceutical companies, including Johnson & Johnson, where he successfully led multiple products through clinical development to regulatory approvals.

Dr. Mulberg received his B.A. from Columbia University and his M.D. from the Mount Sinai School of Medicine. From 1993-2010, he served as Attending Physician in Gastroenterology and Hepatology at Children's Hospital of Philadelphia.

He currently serves as Adjunct Professor of Pediatrics at the University of Maryland School of Medicine, Adjunct Associate Professor of Pediatrics in the University of Pennsylvania School of Medicine and Associate Professor of Pharmacy at the University of the Sciences in Philadelphia.

Dr. Mulberg is also a member of numerous medical organizations including Alpha Omega Alpha Honor Medical Society, American Gastroenterological Association and the North American Society for Pediatric Gastroenterology and Nutrition.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy